Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Clinical Trial ID: NCT04126603

Description

The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells. EPCs are the source of cells protecting the inner lining of blood vessels and improving their survivability will improve cardiovascular outcome as high glucose environment of diabetes are toxic to these EPC Cells. Improve mitochondrial metabolism of Mesenchymal Stem Cell from subcutaneous fatty tissue, leading to weight loss. Improve overall vascular health by reducing inflammation. The investigator will enroll 40 subjects with T2DM who are only on metformin. The study consists of 4 visits to the GW MFA, including screening visit. Subjects will be recruited from across the DMV area, and prescreened over the phone or in clinic, and then invited for an in-person screening visit at the GW MFA to determine eligibility. If eligible, subject will be enrolled into one of two study Arms, active semaglutide 1 mg or Placebo. This study will include an up titration of study drug. From week 0-4 subject will be on 0.25 mg/week, from week 5-8 subject will take 0.5mg/week, and week 9 to 24 subject will take 1 mg/week of Semaglutide or Placebo. During the regular 3 visits subject will have their vital measured, body composition assessed using Tanita scale, arterial stiffness measured and blood drawn for EPC cells analysis and standard of care labs. At visit 1 and visit 3, fat biopsy will be done on the belly area to acquire 2-3 grams of fat tissue. Screening will take place at week -2, Visit1 at week 0, Visit 2 at week 8, Visit 3 at week 24. Subject will receive follow-up phone calls on week 4, week16 and week 28.

Diabetes affects more than 9% of adults in the United States and this is projected to nearly double by 2025. Both diabetes and obesity are associated with endothelial dysfunction, oxidative stress, endothelial cell inflammation, cardiovascular pro-thrombotic states and are the most common causes of kidney disease and blindness. Endothelium and its progenitors, meaning endothelial progenitor cells (EPCs), are an established surrogate of cardiovascular risk outcome measures. EPCs have been defined as CD34+ cells thereby identifying a defined homogenous population from a heterogeneous peripheral blood derived mononuclear cells. The investigator and others, have previously shown that EPCs can act as a cellular biomarker that is more reliable than serum based markers for CVD risk estimation. It was demonstrated that gene expression in EPCs change within two weeks of an intervention such as aerobic exercise. On the other-hand serum biomarkers usually take much longer time to change secondary to an intervention. Also the paracrine effect of damaged endothelium is secondary to gene expression changes that have been altered in the progenitor cells several months ahead of discernible changes in serum based biomarkers such as endothelium based inflammatory markers. When serum inflammatory markers are elevated that may mean that the endothelium is already damaged/ inflamed and possibly irreversibly EPC are the future endothelium, therefore studying EPCs may help us to predict the effect of an intervention (such as a medication or exercise) on the future of endothelium and endothelial function. In normal course of events, the EPCs transition to mature endothelium and replace endothelial cells after normal cell death cycle or programmed apoptosis. However, unfortunately, type 2 diabetes being a pro-inflammatory, high ROS disease process, chronically depletes the EPC population by up-regulating apoptotic pathways mediated by p53. As an apoptotic condition, hyperglycemia even mild (such as prediabetes) affects immature EPCs more so than the mature endothelium. Hence, the damaged and inflamed mature endothelium, with time, is not replaced by EPCs as the progenitor pool has been depleted. This maybe one of the reasons why vascular damage takes 4-5 years to develop following onset of hyperglycemia. It is known that GLP1 agonist has positive effect on oxidative stress, and endothelial function, therefore semaglutide can be hypothesized to have a positive effect on EPC and endothelium and possibly reduce fat inflammation. It may also reduce transformation of multipotent mesenchymal stem cells (MSCs) towards more fat formation (prevent adipogenesis) which may explain weight reducing capability seen in semaglutide studies (SUSTAIN trials). The use of CD34+ cells and MSCs as a biomarker is novel. One can obtain CD34+ cells from a simple peripheral blood draw (without doing an invasive procedure). The blood is then sorted for a homogenous progenitor/stem cell population. Role of CD34+ve EPCs in vascular biology, heart regeneration and collateral vessel formation as an endothelial progenitor cell is well established. It's role as a biomarker is also being developed. CD34+ cells are the most studied cardiovascular progenitor cells and its efficacy has been established in chronic diseases such as diabetes by Werner et al in 2005. Similarly, one can obtain fat derived MSC from fat biopsies, particularly from overweight and obese individuals. Diabetes is not only a state of endothelial dysfunction, it is also a state of fat hyperplasia, insulin resistance at the level of muscle and fat and is associated with high ROS. Improvement of endothelial health is most likely paired with healthier fat. A state of healthier fat will be associated with healthy adipocytes, pre-adipocytes and healthy MSCs. The weight reducing data from SUSTAIN 6 trial using semaglutide at 0.5mg and 1.0mg, is encouraging. It has also shown significant improvement in blood pressure and HbA1C within 8 weeks and definitely by 16 weeks even at a lower FDA approved dose of 0.5mg once a week. These finding prompted the investigator team to use MSC as a fat surrogate and EPCs as an endothelial surrogate to establish a cellular mechanism behind the clinical trial findings. It may also shed light on cross-talk between these two important insulin responsive tissues that contribute towards cardiovascular health. The Investigators believe EPC is the ideal cellular vascular outcome biomarker while MSC is the ideal adipocyte health bio-marker. Based on recently published data on saxagliptin's effect on EPC of subjects with Type 2 Diabetes, the investigators are confident that EPC is a robust endothelial marker with quick changes in number, function and gene expression, after appropriate intervention. The purpose of the present study is to study the effect of a long-acting GLP-1 agonist, over a period of 24 weeks and understand how it influences two different yet related cell types such as endothelium and adipocyte, both of which are key players in insulin resistance/sensitivity in the body. Study Hypotheses: The investigator hypothesize that GLP1 agonists, like semaglutide, have a positive effect on the EPC number, function, targeted gene expression, arterial stiffness and endothelium specific inflammatory markers. Additionally, the investigator hypothesize that semaglutide therapy will reduce adipogenesis and increase bone and cartilage formation by increasing cellular metabolism, as evidenced by increased mitochondrial biogenesis and increased cellular oxygen consumption rate (OCR, measured by SeaHorse).


Criteria

Inclusion Criteria: 1. Age 30-70 2. Diagnosed with Type 2 diabetes mellitus 3. Body Mass Index (BMI) between 25.0-45.0 (both inclusive) 4. eGFR ≥ 30 mL/min/1.73 m2 by MDRD 5. HbA1C 7.0 - 10.0 % 6. Subjects on a stable dose of Metformin (1-2 grams), only, for 3 months prior to screening. 7. Ability to provide informed consent (and document informed consent by signature) before any trial-related activities are conducted. 8. Additional CVD risk factor such microalbuminuria or proteinuria (as defined by ADA, UACR > 30 mg/g), hypertension (labile and uncontrolled hypertension) and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an ankle- brachial index the ratio of the systolic blood pressure at the ankle to the systolic blood pressure in the arm of less than 0.9, low HDL with hypertriglyceridemia (as defined by NCEP ATP III) , strong family history of CHD (as defined by NCEP ATP III and ATP IV). 9. Retinal examination within last 18 months of enrollment, showing no proliferative retinopathy Exclusion Criteria: 1. Uncontrolled hyperglycemia with fasting glucose >240 mg/dL (>13.3 mmol/L) 2. Liver disease with ALT, AST or ALP ≥ x3 ULN 3. Planned CV surgery or angioplasty in the past 1 month 4. History of established CVD 5. Known personal history of cerebral stroke or heart attack ( myocardial infarction) 6. All other diabetes medications other than metformin 7. Personal or family history of medullary thyroid cancer (MTC) 8. Personal or family history of Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) 9. GFR <30 mL/min/1.73 m2 by MDRD 10. Prior surgery with chronic malabsorption (eg, bariatric) in prior 1 year 11. Clinically significant RBC disorders such as hemoglobinopathies 12. Diagnosis of Type 1 diabetes mellitus or history of GAD antibody positive status 13. Chronic use of anti-inflammatory drugs for the last 3 months 14. Beginning statin medications or change in statin dose in the past 1 month 15. Use of consistent long-term steroid medication (oral, inhaled, injected) within the last 1 month 16. History of pancreatitis 17. Known or suspected allergy to GLP-1 agonists, excipients, or related products. 18. Active smokers 19. Active wounds (i.e. diabetic ulcers) or recent surgery within 1 month 20. Untreated hyper/hypothyroidism 21. Implanted devices (eg. Pacemaker) that may interact with Tanita scale 22. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial 23. Women of child bearing potential who are not willing to use a contraceptive method to avoid pregnancy for the 16 weeks of study duration plus 2 months post treatment (for semaglutide washout). 24. Women who are pregnant or breastfeeding 25. Chronic or persistent alcohol or drug abuse 26. Prisoners or subjects who are involuntarily incarcerated 27. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg. infectious disease) illness 28. Participation in another trial with an investigational drug within 30 days prior to informed consent. 29. Untreated or active hemorrhagic proliferative diabetic retinopathy Exclusionary Laboratory Findings 30. Chronic Kidney Disease (CKD) stages 4 and 5 (estimated CrCl less than 30 mL/min) 31. Serum creatinine levels ≥1.8 with estimated CrCl < 60 mL/min 32. Triglycerides > 500 mg/dL 33. Low hematocrit (<28 Units)

  • Start Date

    2019-08-01

  • Last Updated

    2019-10-11

  • Sponsor

    Sabyasachi Sen

  • Condition Name

    Diabetes Mellitus, Type 2

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.